Abstract: Systems, methods, and apparatus are provided for generating an atlas image of a branched structure and predicting a likelihood of success of certain treatments based on the atlas image. In one example, a method includes registering a plurality of images of instances of a branched structure to generate an aligned image for a cohort, wherein the branched structure comprises a central structure and at least one primary branch connected to the central structure; for each primary branch of the branched structure, iteratively registering respective portions of a plurality of images containing the primary branch to generate an aligned image portion of the primary branch; and applying a control grid of the aligned image portion of the primary branch to respective image portions containing the central structure and the other primary branches prior to iteratively registering a next primary branch; and generating an atlas image for the cohort based on the aligned image portions.

Abstract: The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Abstract: The present invention relates to compositions comprising 5-fluorouracil, or a pharmaceutically acceptable salt or analogue thereof, folinic acid, or a pharmaceutically acceptable salt thereof and a cyclodextrin, or a pharmaceutically acceptable salt or derivative thereof. The invention also relates to methods for the treatment of cancer using such compositions.

Abstract: The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Abstract: The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Abstract: A shelf stable, high moisture hot-aerated dairy product is disclosed that comprises a mixture of about 10 to about 66% of a dairy component, about 20 to about 30% of a fat component, and about 0.5 to about 2.5% of a stabilizer system. The stabilizer system comprises at least a two gum system, where one gum is gelatin, or at least a three gum system, where one gum is either gelatin or carrageenan with the remaining gums being different. The mixture is aerated to about 2% to about 20% overrun while the mixture is still hot and is subsequently filled into packages at the high temperature, i.e., from about 140° F. to about 180° F. The resultant dairy product has a shelf life of at least 12 months when stored at ambient temperatures or at least 18 months when stored at refrigeration temperatures without requiring aseptic processing or packaging techniques.

Abstract: The present invention relates to compositions comprising 5-fluorouracil, or a pharmaceutically acceptable salt or analogue thereof, folinic acid, or a pharmaceutically acceptable salt thereof and a cyclodextrin, or a pharmaceutically acceptable salt or derivative thereof. The invention also relates to methods for the treatment of cancer using such compositions.

Abstract: The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Abstract: A single SAN management utility is disclosed that discovers all hosts and HBAs in a SAN, configures the storage switches, creates Logical Units within a storage array, and assigns Logical Units to the hosts in the SAN without requiring the administrator to have a detailed understanding of all of the devices in the SAN or a SAN configuration plan. The SAN management utility may first invoke HBA configuration routines to discover and configure the HBAs in the SAN and determine the hosts in which those HBAs reside. The SAN management utility may then utilize the SAN link to set a new IP address for the storage switch, and then configure the switch over an Ethernet connection. In addition, the SAN management utility may interface with a configuration utility in the storage array through a common storage management specification to create and assign Logical Units in the storage array.

Abstract: Providing a virtual device container to virtually extend the functionality of a network device on a network for supporting a plurality of functional application modules residing in a server on the network, including receiving a function request sent from one of the functional application modules, the function request corresponding to the network device, and selecting one of a plurality of functional component modules in response to the function request, each of the functional component modules corresponding to a respective one of the functional application modules, the selected functional component module corresponding to the functional application module which sent the function request.

Abstract: Interfacing a plurality of virtual device container modules to a third-party application, each of the virtual device container modules being in communication with a tracker module through a software bus, including receiving an interface command at the interface module from the third-party application via a third-party connection, the interface command relating to a designated one of the plurality of virtual device container modules, establishing a direct connection between the interface module and the designated virtual device container module by using an address pointer, receiving information data, at the interface module, from the designated virtual device container module via the direct connection, the information data relating to the designated virtual device container module, and sending the information data from the interface module to the third-party application via the third-party connection.

Abstract: Disclosed are methods for diagnosing, monitoring the progression of, and treating a prostate disorder based upon genes that are differentially expressed in prostate disorders. Also disclosed are methods for identifying agents useful in the treatment of a prostate disorder, methods for monitoring the efficacy of a treatment for a prostate disorder, methods for inhibiting the proliferation of a prostate cell, and prostate-specific vectors including the promoter of these genes.

Abstract: Interfacing a plurality of virtual device container modules to a third-party application, each of the virtual device container modules being in communication with a tracker module through a software bus, including receiving an interface command at the interface module from the third-party application via a third-party connection, the interface command relating to a designated one of the plurality of virtual device container modules, establishing a direct connection between the interface module and the designated virtual device container module by using an address pointer, receiving information data, at the interface module, from the designated virtual device container module via the direct connection, the information data relating to the designated virtual device container module, and sending the information data from the interface module to the third-party application via the third-party connection.

Abstract: A spin valve device containing a chromium or chromium and aluminum antiferromagnetic layer, which acts as a pinning layer for a magnetoresistive ferromagnetic layer, by exchange coupling. The antiferromagnetic layer has a tunable Neel temperature and anisotropy constant, and is corrosion resistant.

Abstract: A method of moulding an article having areas of color contrast on the surface comprising coating one surface of a mould with a colored composition prior to filling the mould with a curable composition of contrasting color and curing the composition characterised in that the colored composition comprises at least 25% by weight of(a) a fluid carrier comprising a mixture of 0-100 parts by weight of a polymerizable liquid and correspondingly 100 to 0 parts by weight of a non-polymerizable, volatile, organic solvent,(b) from 0.1 to 10% by weight of the total composition of a colorant in the form of an inorganic pigment or carbon black, or 0.0001 to 1% by weight of an organic pigment or dye,(c) from 0 to 60% by weight of the total composition of a finely divided filler, preferably having a mean particle size of less than 2 microns,(d) 0.

Abstract: Process for treating used lubricating oil to reduce the content of suspended particulate matter therein, characterized by contacting said used lubricating oil with a carbonyl-group containing compound in the presence of an aqueous electrolyte, separating the resulting mixture into an upper layer containing clarified oil and a lower layer containing agglomerated particulates, and recovering oil of reduced particulate content as product. Suitable carbonyl-group containing compounds include ketones, esters and aldehydes and suitable electrolytes include inorganic and organic acids, alkalis and salts.

Abstract: A method of moulding a shaped article from a curable composition in which the composition is cured in a mould comprising at least two mould parts defining a cavity characterized in that prior to introducing the curable composition into the mould cavity, the pressure inside the cavity is increased above atmospheric pressure, preferably to at least 0.3 bar above atmospheric pressure, the dispersion is injected into the mould against this pressure and is subsequently cured. The method is useful for overcoming problems of color banding on the surface of the moulding which originate in the filling process and are particularly evident when high mould temperatures are used.

Abstract: A method of moulding a shaped article from a curable composition in which the composition is cured in a mould comprising at least two mould parts defining a cavity characterized in that prior to introducing the curable composition into the mould cavity, at least part of the surface forming the mould cavity is provided with a deposit of a material which provides a color contrast with the curable composition, the deposit being provided on areas of the mould which correspond to the areas on the cured moulding on which the color contrast is required to be reproduced, the deposit consisting of at least one finely divided pigment mixed with at least one finely divided filler. Preferably the weight ratio of filler to pigment is in the range 1:1 to 100:1, desirably 5:1 to 50:1. Sufficient deposit is applied to give the desired color contrast effect in the finished moulding.